glp-1 coverage medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing Medicare to cover GLP-1

Who injections are better for: People who want evidence-based, FDA-approved therapy Those eligible for insurance reimbursement Patients with diabetes or cardiovascular risks Anyone prioritizing consistent, measurable results Who patches may appeal to: People afraid of needles Curious biohackers who want to try supplements rather than true GLP-1s Those willing to experiment with their health Expert Opinion C

doi: 10.25259/AJBPS_19_2025 Abstract Epilepsy is a chronic neurological disorder characterized by recurrent seizures and remains a major global concern, particularly when resistance to conventional anti-epileptic drugs limits treatment success

To view or add a comment, sign in Delighted to see the global reach of this life-saving technology continue to expand The burden of #hypertension, particularly #uncontrolled and #resistant hypertension, is staggering - every tool helps in the fight Proud to work with a company, Recor Medical, interested in entering new markets for the *right* reasons #innovation #medtech #cardiology #interventionalcardiology The ultrasound-based RDN tech from Recor Medical is now available in Japan, home to an estimated 43 million adults with hypertension

However, the absence of statistically significant effects of GLP-1R agonists, with respect to at least one fibrosis stage histological improvement without worsening of NASH, could be the result of: (i) the insufficient duration of the current studies